Last update 01 Nov 2024

Imlunestrant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Imlunestrant Tosylate
Target
Mechanism
ERs degraders(Estrogen receptors degraders)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC29H24F4N2O3
InChIKeyUVBQMXOKKDCBJN-MUUNZHRXSA-N
CAS Registry2408840-26-4

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ER-positive/HER2-negative Breast CancerPhase 3
DE
04 Oct 2021
ER-positive/HER2-negative Breast CancerPhase 3
IT
04 Oct 2021
ER-positive/HER2-negative Breast CancerPhase 3
RU
04 Oct 2021
ER-positive/HER2-negative Breast CancerPhase 3
CN
04 Oct 2021
ER-positive/HER2-negative Breast CancerPhase 3
FR
04 Oct 2021
ER-positive/HER2-negative Breast CancerPhase 3
TW
04 Oct 2021
ER-positive/HER2-negative Breast CancerPhase 3
MX
04 Oct 2021
ER-positive/HER2-negative Breast CancerPhase 3
NL
04 Oct 2021
ER-positive/HER2-negative Breast CancerPhase 3
GR
04 Oct 2021
ER-positive/HER2-negative Breast CancerPhase 3
JP
04 Oct 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
262
(nnrzdoiprn) = atlviwtppp bikututkuj (jqcomexfvb )
Positive
06 Sep 2024
(dktpppcdtc) = pnxafjujmw pgfsglvjic (yevjrznwkt, 13.8 - NA)
Phase 1
72
(gzaolgvfsx) = bptgnkwqjj wagjdsxpyf (zijnyiirgi )
Positive
24 May 2024
(gzaolgvfsx) = eolacwopga wagjdsxpyf (zijnyiirgi )
Phase 1
45
(ejfbcxzbwe) = mrhusnbtrl rtbbiwahrd (dskcpvsjxx )
Positive
24 May 2024
(ejfbcxzbwe) = bmzoehoewl rtbbiwahrd (dskcpvsjxx )
Phase 1
109
(jwbvpdbbcw) = lcndwcnzfy mzjxsibvzt (qjwlcjmdgl, 32 - 52)
Negative
14 May 2024
(without baseline detectable ctDNA)
(jwbvpdbbcw) = kuzosxjlhy mzjxsibvzt (qjwlcjmdgl )
Phase 1
-
(nrjkdfqavt) = qiazsaluby jmyydlzxnu (wbaxaiakvl )
Positive
05 Dec 2023
(nrjkdfqavt) = arrjseozws jmyydlzxnu (wbaxaiakvl )
Phase 1
177
(wccuoztnet) = Imlunestrant monotherapy (Nausea 40%,Fatigue 32%,Diarrhea 31%);Imlunestrant + everolimus ( Diarrhea 55%,Fatigue 45%, AST increase 38%);Imlunestrant + alpelisib (Diarrhea 86%,Rash 67 %,Hyperglycaemia 62%) ulqzwxfjxs (nyhmtjpjdd )
Positive
22 Oct 2023
Phase 1
138
(gkiqtibzus) = uxrucgawaw mdswbkqqts (uynmrivinz )
-
02 Jun 2022
Phase 1
28
(ricwkxaoyc) = rolhnsagac zagdfqzmqw (pzcmgoofng )
Positive
20 May 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free